SCHEMBL12430675

SCHEMBL12430675

CCCc1ccc(Nc2nc(Nc3cc(C4CC4)[nH]n3)c3ccccc3n2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 4/20 0.74
NTRK1 P04629 2/20 0.67
PDK1 Q15118 1/20 0.60
ULK2 Q8IYT8 1/20 0.60
NTRK3 Q16288 1/20 0.58
NTRK2 Q16620 1/20 0.58
GSK3B P49841 4/20 0.56
SRC P12931 3/20 0.56
AURKA O14965 1/20 0.56
PAK4 O96013 2/20 0.55
PAK1 Q13153 1/20 0.55
IGF1R P08069 5/20 0.55
AURKB Q96GD4 2/20 0.53
CCNA2 P20248 1/20 0.52
CDK2 P24941 1/20 0.52
DYRK3 O43781 1/20 0.52
JAK2 O60674 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
ABL1 P00519 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430674 0.92 ULK1 (0.77) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL12430676 0.91 ULK1 (0.74) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL31471779 0.88 ULK1 (0.86) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL12430667 0.88 ULK1 (0.86) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL12430688 0.86 ULK1 (0.73) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL31471925 0.86 ULK1 (0.73) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL12430680 0.86 ULK1 (0.73) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL30770809 0.86 ULK1 (0.73) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL31471724 0.85 ULK1 (1.00) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL31471772 0.85 ULK1 (0.81) ULK1NTRK1PDK1ULK2NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA ULK1 965/4885NTRK1 2111/4885PDK1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.